1.3. Treating and managing disease

There is a need to support the improvement of cross-cutting support technologies for drugs, biotherapies, vaccines and other therapeutic approaches, including transplantation, surgery, gene and cell therapy and nuclear medicine; to increase success in the drug and vaccine development process (including alternative methods to replace classical safety and effectiveness testing, e.g. the development of new methods); to develop regenerative medicine approaches, including approaches based on stem cells; to develop new biopharmaceuticals, including therapeutic vaccines; to develop improved medical and assistive devices and systems; to improve palliative therapies; to maintain and enhance the ability to combat disease and undertake medical interventions that depend on the availability of effective and safe antimicrobial drugs; and to develop comprehensive approaches to treat co-morbidities at all ages and avoid poly-pharmacy. These improvements will facilitate the development of new, more efficient, effective, sustainable and personalised treatments for disease and for the management of disability and frailty, including advanced therapies and cellular therapies for the treatment of chronic diseases. Clinical trials are an important means to transfer biomedical knowledge to application in patients, and support for these will be provided, as well as for the improvement of their practice. Examples include the development of better methodologies to allow trials to focus on relevant population groups, including those suffering from other concomitant diseases and/or already undergoing treatment; the determination of comparative effectiveness of interventions and solutions; and enhancing the use of databases and electronic health records as data sources for trials and knowledge transfer. Pre-clinical and/or clinical development of designated orphan drugs will be supported. Similarly, support for the transfer of other types of interventions, such as those related to independent living, into real world environments will be provided.

← anx_I__cpt_1__cpt_6__cpt_1__cpt_2__cpt_3__text_1 · All articles · 1.3.1. Treating disease, including developing regenerative medicine →

Source: EUR-Lex (Cellar) · retrieved 2026-11-04 · Text as adopted (Official Journal); later amendments are not incorporated in this text.